Celldex Therapeutics Inc (NASDAQ: CLDX) started the day on Wednesday, with a price increase of 3.89% at $27.24, before settling in for the price of $26.22 at the close. Taking a more long-term approach, CLDX posted a 52-week range of $14.40-$31.66.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 6.91%. Meanwhile, its Annual Earning per share during the time was 6.91%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -41.33%. This publicly-traded company’s shares outstanding now amounts to $66.39 million, simultaneously with a float of $64.52 million. The organization now has a market capitalization sitting at $1.81 billion. At the time of writing, stock’s 50-day Moving Average stood at $23.83, while the 200-day Moving Average is $21.95.
Celldex Therapeutics Inc (CLDX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Celldex Therapeutics Inc’s current insider ownership accounts for 2.84%, in contrast to 108.81% institutional ownership. According to the most recent insider trade that took place on Aug 13 ’25, this organization’s SVP & GENERAL COUNSEL sold 771 shares at the rate of 24.77, making the entire transaction reach 19,096 in total value, affecting insider ownership by 34,962. Preceding that transaction, on Nov 11 ’24, Company’s PRESIDENT & CEO bought 11,500 for 26.82, making the whole transaction’s value amount to 308,430. This particular insider is now the holder of 40,284 in total.
Celldex Therapeutics Inc (CLDX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.93 per share during the current fiscal year.
Celldex Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -41.33% and is forecasted to reach -4.15 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -19.33% through the next 5 years, which can be compared against the 6.91% growth it accomplished over the previous five years trading on the market.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Let’s observe the current performance indicators for Celldex Therapeutics Inc (CLDX). It’s Quick Ratio in the last reported quarter now stands at 19.67. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 312.42.
In the same vein, CLDX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.01, a figure that is expected to reach -0.90 in the next quarter, and analysts are predicting that it will be -4.15 at the market close of one year from today.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
If we take a close look at the recent performances of Celldex Therapeutics Inc (NASDAQ: CLDX), its last 5-days Average volume was 0.9 million that shows plunge from its year to date volume of 1.03 million. During the previous 9 days, stock’s Stochastic %D was recorded 78.67% While, its Average True Range was 68.54.
Raw Stochastic average of Celldex Therapeutics Inc (CLDX) in the period of the previous 100 days is set at 93.64%, which indicates a major rise in contrast to 84.47% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.02 that was lower than 1.22 volatility it exhibited in the past 100-days period.
